Navigation Links
Healthpoint Biotherapeutics Acquires Regranex® Gel
Date:6/2/2011

rolonged, non-healing, inflammatory state). Chronic wounds are often derivative of another illness or condition such as diabetes, obesity, peripheral vascular disease and immobility.

Diabetic foot ulcers are those that occur in individuals with diagnosed diabetes mellitus with peripheral neuropathy. These wounds are considered inherently difficult-to-heal and at risk of becoming chronic due to the underlying disease state interfering with the normal healing process. The longer it takes for a wound to heal, the greater the likelihood of complications.

It is estimated that 7% or 20.8 million people have diabetes in the Unites States alone, and the incidence is expected to increase some 14% annually. Of those diagnosed with diabetes, up to 15% will develop a diabetic foot ulcer in their lifetime, and up to 59% will have recurrence of their foot ulcers, leading to over 82,000 amputations annually.  The total annual direct cost of non-infected diabetic ulcer treatment has been estimated at over $6 billion.

"Non-healing diabetic foot ulcers are the number one cause of non-traumatic amputations in the United States," said Bert Slade, MD, Chief Medical Officer of Healthpoint Biotherapeutics.  "Regranex® Gel continues to be an important option in the therapeutic armamentarium for patients with these wounds."

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and Regranex® Gel. He
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Talecris Biotherapeutics Announces First Quarter 2011 Results
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Northwest Biotherapeutics Addresses Recent Market Activity
7. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
8. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
9. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
10. Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
11. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... 25 BN,ImmunoTherapeutics, Inc. announced today that the ... licensed from the National Institutes of,Health (NIH) is ... the,excellent safety and efficacy results previously reported, will ... on February 26-28, 2009 in,Orlando, Florida. , ...
... 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ... researching,developing, manufacturing and marketing biopharmaceutical products, today,announced that ... quarter and,full year ended December 31, 2008 after ... , Following the earnings ...
... Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled ... patch Phase III program. The program consists of ... Cerimon,s diclofenac patch. The studies will assess the ... placebo for the treatment of acute pain caused by ...
Cached Biology Technology:BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 33SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:9/2/2014)... September 2, 2014 In a new study that ... the Florida campus of The Scripps Research Institute (TSRI) ... into unique manufacturing sites for molecules that can treat ... cell as a reaction vessel and a disease-causing defect ... diseased cell," said TSRI Professor Matthew Disney.,"Because the treatment ...
(Date:9/2/2014)... research suggests that professional baseball pitchers with poor core stability ... a single season because of injury than are pitchers who ... pelvis. , In the study, 347 pitchers were assessed for ... their pelvis as they raised a leg to step up ... least 30 days cumulative, not consecutive during the ...
(Date:9/2/2014)... think losing weight is enough to prevent Type 2 diabetes, ... September 2014 issue of The FASEB Journal ... develop Type 2 diabetes. This study compared genetically identical twins-one ... meal, the circulating metabolites, including those related to Type 2 ... These findings suggest that the onset of this type ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 ... from human DNA fragmentation factor (DFF). The sequence of ... - P - K - S - V - K ... - S - P - R - K(18). ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... High Throughput Processing of Microarrays Using the ... Frame multiple slide plate is designed to ... corresponding multi-well incubation chambers in a microplate ... The footprint dimensions meet the standards recommended ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: